Transition Therapeutics (Transition Therapeutics) Price-to-Tangible-Book : 4.03 (As of Apr. 26, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Transition Therapeutics Price-to-Tangible-Book?

As of today (2024-04-26), Transition Therapeutics's share price is $1.5248. Transition Therapeutics's Tangible Book per Share of Mar. 2016 for the quarter that ended in Mar. 2016 was $0.38. Hence, Transition Therapeutics's Price to Tangible Book Ratio of today is 4.03.

The historical rank and industry rank for Transition Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

TTHI's Price-to-Tangible-Book is not ranked ^*
in the Biotechnology industry.
Industry Median: 2.68
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Transition Therapeutics's share price is $1.5248. Transition Therapeutics's Book Value per Sharefor the quarter that ended in Mar. 2016 was $0.53. Hence, Transition Therapeutics's P/B Ratio of today is 2.90.

Transition Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Transition Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transition Therapeutics Price-to-Tangible-Book Chart

Transition Therapeutics Annual Data

Trend

Jun06

Jun07

Jun08

Jun09

Jun10

Jun11

Jun12

Jun13

Jun14

Jun15

Price-to-Tangible-Book

Get a 7-Day Free Trial

3.61

3.82

3.72

5.03

3.52

Transition Therapeutics Quarterly Data
	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16
Price-to-Tangible-Book	Get a 7-Day Free Trial															7.90	3.52	3.73	4.44	3.39

Competitive Comparison of Transition Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Transition Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Transition Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transition Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Transition Therapeutics's Price-to-Tangible-Book falls into.

Transition Therapeutics Price-to-Tangible-Book Calculation

Transition Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Mar. 2016 )
	=	1.5248	/	0.378
	=	4.03

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Transition Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Transition Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Transition Therapeutics (Transition Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transition Therapeutics Inc (NAS:TTHI) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.transitiontherapeutics.com

Transition Therapeutics Inc was incorporated on July 6, 1998 as 'Transition Therapeutics and Diagnostics Inc.' The Corporation filed articles of amendment on October 12, 2000 and on October 19, 2000 to create a class of non-voting shares (the 'Class B Shares') and to amend certain attributes of its Common Shares. On November 2, 2000, the Corporation filed articles of amendment to delete its private company restrictions. On December 14, 2000, the Corporation filed articles of amendment to change its name to 'Transition Therapeutics Inc.' The Company's technologies are focused on the treatment of Alzheimer's disease and diabetes. The Corporation operates in one business segment; that is the research and development of therapeutic agents. Its technologies in development include ELND005 (AZD-103) for the treatment of Alzheimer's disease. On April 30, 2013, the Company announced the results of a five-week proof of concept clinical study of TT401 in type 2 diabetic and obese non-diabetic subjects. In the study, TT401, a once weekly administered peptide, demonstrated improvements in glycemic control and reductions in body weight.

Executives

Jack W Schuler	10 percent owner	100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Family Foundation Schuler	10 percent owner	100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045

Transition Therapeutics (Transition Therapeutics) Headlines

From GuruFocus

Hardest Hit Companies of the Day: Transition Therapeutics Inc., Sunesis Pharmaceuticals Inc., GenCorp Inc., Cyclacel Pharmaceuticals Inc., FactSet Research Systems Inc.

By guruek guruek • 12-15-2009